A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies-Reference-Cited by-同舟云学术

A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies

Published:2021-01 Issue:1 Volume:58 Page:35-44
ISSN:0037-1963
Container-title:Seminars in Hematology
language:en
Short-container-title:Seminars in Hematology

Author:

Hill Brian,Jagadeesh Deepa,Pohlman Brad^ORCID,Dean Robert^ORCID,Parameswaran Neetha,Chen Joel,Radivoyevitch Tomas^ORCID,Morrison Ashley,Fada Sherry^ORCID,Dever Meredith^ORCID,Robinson Shelley,Lindner Daniel^ORCID,Smith Mitchell,Saunthararajah Yogen^ORCID

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Hematology

Reference63 articles.

1. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene;Pinyol;Am J Pathol,2000

2. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas;Vasmatzis;Blood,2012

3. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma;Delfau-Larue;Blood,2015

4. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors;Mak;J Clin Oncol,2013

5. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses;Coiffier;J Hematol Oncol,2014

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy;Cell Reports;2023-08

2. Epigenetic targets in B- and T-cell lymphomas: latest developments;Therapeutic Advances in Hematology;2023-01

3. Epigenetic therapy of cancer;Medicinal Chemistry of Anticancer Drugs;2023

4. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine;Leukemia & Lymphoma;2022-11-12

5. Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas;International Journal of Cancer;2022-06-16